NCT01994837View on ClinicalTrials.gov

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

PHASE2CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Acute Myelogenous LeukemiaAMLAcute Myeloid Leukemia

Interventions

DRUG

ABT-199

Tablet

Sponsors

Lead Sponsor

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

AbbVie

INDUSTRY